[5] [6] However, retatrutide remains an investigational compound and has not been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for any clinical use
The safety and efficacy profile in non-diabetic populations is not established
Liraglutide, semaglutide and dulaglutide have demonstrated cardiovascular benefits, and Wegovy recently added to this evidence base: in the SELECT trial, patients on Wegovy had a 20% lower incidence of heart attack, stroke or death from heart disease compared to those on a placebo
After full-text assessment, we excluded studies on diabetes mellitus ( n = 154), studies on Parkinson or neurodegenerative conditions ( n = 8), and in vitro, animal and human studies that did not investigate pain as primary and/or secondary outcome ( n = 130)
What Are GLP-1 Patches
10.1080/10590501.2013.844757 J